Prevalence and antimicrobial resistance patterns of Campylobacter spp. Causing human gastroenteritis in Iran (2000–2025): a systematic review and meta-analysis Authors: Mozhgan Derakhshan-sefidi, Bita Bakhshi, Farzaneh Hamidi, Sahel Safaei, Saeed Shams, Anoshirvan Kazemnejad, Sareh Bagheri-Josheghani Published: 2025 ABSTRACT AbstractAimCampylobacteriosis is a major cause of gastroenteritis globally, but comprehensive data on its prevalence and antimicrobial resistance (AMR) patterns in Iran are limited. This study aimed to estimate the national prevalence of Campylobacter-associated gastroenteritis in Iran, analyze temporal trends in infection rates, and characterize antibiotic resistance patterns among circulating Campylobacter spp. over the past two decades.MethodsIn accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, a systematic search was performed across the Web of Science, PubMed, Scopus, Embase, Islamic World Science Citation Center (ISC), Scientific Information Database (SID), and Magiran databases for studies published from 2000 to 2025. Eligible studies were assessed based on predefined inclusion criteria, followed by both qualitative and quantitative analyses of the selected studies. The quality of the studies was evaluated using the Joanna Briggs Institute (JBI) Critical Appraisal Checklist, and data analysis was conducted utilizing the R statistical programming language along with the ‘meta’ package. A random-effects model was applied to calculate the pooled prevalence, while heterogeneity was measured using the I² statistic and a prediction interval.ResultsA total of 46 studies met the inclusion criteria. Meta-analysis using a random-effects model revealed an overall pooled prevalence of 8.0% (95% CI: 6.0–10.0%), with substantial heterogeneity among studies (I² = 97.0%, p < 0.0001), likely due to variability in diagnostic methods, populations, and study designs. Subgroup analysis showed a higher prevalence for C. jejuni (35.0%, 95% CI: 22.0–49.0%, I² = 98.5%) compared to C. coli (16.0%, 95% CI: 11.0–22.0%, I² = 75.5%), while C. lari was excluded due to rarity. A temporal assessment revealed a peak prevalence of 11.0% (95% CI, 7.0–15.0%, I² = 94.2%) during the period 2013–2020, indicating a general upward trend over time. In patients ≤ 10 years, prevalence was 6.0% (95% CI, 3.0–9.0%, I² = 92.1%), with C. jejuni and C. coli responsible for 45.0% (95% CI, 13.0–80.0%) and 14.0% (95% CI, 7.0–23.0%) of cases, respectively. Among those ˃ 10 years, prevalence was 8.0% (95% CI, 6.0–11.0%, I² = 97.6%), with 32.0% (95% CI, 18.0–47.0%) for C. jejuni and 16.0% (95% CI, 10.0–24.0%) for C. coli. Resistance to ciprofloxacin (65%; higher in C. coli) and nalidixic acid (98%; higher in C. jejuni) — both quinolones—has shown a consistent and sharp increase, reaching the highest resistance levels in recent years. Similarly, tetracycline (79%; higher in C. coli) resistance has followed a rising trend, particularly in C. coli and overall Campylobacter spp., making these antibiotics increasingly ineffective for empirical treatment.ConclusionThis systematic review and meta-analysis highlight a moderate but rising prevalence of gastroenteric Campylobacter infections in Iran, with C. jejuni being the predominant species. Increasing resistance to quinolones, tetracyclines, and macrolides poses a serious threat to treatment, especially in C. coli. While gentamicin shows sustained low resistance, its parenteral administration restricts routine use, limiting its role to severe cases. Strengthened national surveillance, standardized diagnostics, and robust antimicrobial stewardship, particularly in poultry—the main source of human disease—are urgently needed.Clinical trial numberNot applicable.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12879-025-12057-0.Keywords: Prevalence, Campylobacter, Meta-analysis, Drug resistance, Iran Introduction Campylobacter (C.) is a genus of Gram-negative, slender, spiral-shaped bacteria equipped with flagella, classified within the rRNA superfamily VI of the Proteobacteria class [1]. Pathogenic species that infect humans and animals are mainly identified through phylogenetic methods [2]. As a zoonotic pathogen, campylobacters are most commonly associated with poultry [3], although other sources, such as flies [4], unpasteurized milk, and contaminated water/food also contribute to their transmission [5, 6]. Direct contact with asymptomatic infected animals is another route of infection [7]. The widespread colonization of environmental and animal reservoirs makes Campylobacter a major source of foodborne and environmental contamination, posing a significant public health risk [8]. Campylobacter has a strikingly low infectious dose: ingesting roughly 500–800 cells typically causes illness in humans [9]; and some studies suggest infection may occur with as few as ~ 100 cells, or even fewer [10]. This variability may be influenced by disease severity, the dose-response relationship, and the virulence of specific Campylobacter strains [11]. Campylobacter spp. is responsible for an estimated 400–500 million infections and over 21,000 deaths worldwide each year [12, 13]. While many infections are asymptomatic, Campylobacter spp. are known to be a major cause of gastrointestinal diseases can also lead to serious systemic diseases such as endocarditis, septicemia, cholecystitis, and urinary tract infections [14, 15]. Although most acute Campylobacter spp. infections are self-limiting; in rare cases, they may lead to severe long-term complications such as Guillain–Barré syndrome [16], peripheral neuropathies [17], Miller-Fisher syndrome [18], and functional bowel disorders such as irritable bowel syndrome [2]. The disease caused by this genus is called campylobacteriosis, which is an intestinal infection and usually presents with gastrointestinal symptoms such as abdominal pain, diarrhea, fever, nausea, and vomiting [19]. While campylobacteriosis is usually mild and self-limiting, severe cases involving dehydration, dysentery, and high fever can sometimes be fatal [20]. The infection poses a greater risk of serious complications in children, the elderly, and immunocompromised individuals. The genus Campylobacter spp. can be isolated from both symptomatic patients and healthy carriers, with Campylobacter jejuni accounting for the majority of infections and Campylobacter coli causing a smaller proportion [21]. Diarrhea caused by Campylobacter is more commonly observed in children than in adults [22]. In developed countries, Campylobacter infections are mostly sporadic with a clear summer peak (June–August) [3, 23], likely driven by broiler contamination and outdoor cooking/hygiene risks [4, 24]. In developing countries, they are endemic, characterized by more asymptomatic carriage and limited seasonality, which is sustained by poor sanitation, limited hygiene, and close contact with poultry/livestock [25–27]. Antimicrobial therapy shortens illness when the infecting strain is susceptible [28]; treatment is typically reserved for persistent symptoms or high-risk patients, with macrolides as first-line and fluoroquinolones as second-line options [29]. Rising resistance in Campylobacter increases the risk of therapeutic failure, prompting consideration of alternatives such as tetracyclines, aminoglycosides, and amphenicols [30]. Reflecting the global threat, the WHO lists fluoroquinolone-resistant Campylobacter as a high-priority pathogen, underscoring the need for new research and drug development [31, 32]. Against this backdrop, defining Campylobacter prevalence and resistance patterns in Iran is critical. Hence, this systematic review and meta-analysis aimed to (1) determine the overall prevalence of Campylobacter-induced gastroenteritis in Iran, with a focus on patients under 10 years of age; (2) assess temporal trends in infection rates; and (3) evaluate the antibiotic resistance patterns of circulating Campylobacter spp. over the past two decades. Methods This systematic review and meta-analysis were conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [33]. Literature search strategy and selection A comprehensive scientific search on the prevalence and antimicrobial resistance characteristics of Campylobacter spp. gastroenteritis in Iran was carried in valid electronic global databases, including PubMed, Scopus, Web of Science, Embase, ISC, SID, and Magiran. The search was performed through systematic research from 2000 to 2025 (File S1). All eligible articles were retrieved using relevant search terms and keywords, which included “Campylobacter spp.,” “drug resistance,” “Iran,” “gastroenteritis,” “Campylobacter coli,” and “Campylobacter jejuni”. Relevant articles were identified through comprehensive searches using Boolean operators (“AND,” “OR”) and by manually screening the reference lists of selected publications. For data management, EndNote Reference Manager version 9.5 was used to import reference lists and to check and eliminate duplicate studies. Eligibility criteria Inclusion and exclusion criteria Only studies conducted in Iran involving human participants were included in this research. The inclusion criteria for this review were: publications in either English or Persian; studies involving inpatient or outpatient participants of any sex; and investigations using stool or rectal samples related to gastroenteritis-associated campylobacteriosis, confirmed by molecular or microbiological tests. Only studies conducted in Iran were considered. For antimicrobial resistance analysis, studies had to include data on at least one of the following six antibiotics: nalidixic acid, tetracycline, ciprofloxacin, erythromycin, ampicillin, or gentamicin. These antibiotics were selected based on their clinical relevance in the treatment of Campylobacter infections and their consistent reporting across the reviewed literature. The exclusion criteria were as follows: studies that were not fully accessible; books; review articles; literature reviews; conference proceedings; book chapters; letters or letters to the editor; and case reports. Persian-language articles without an English abstract were also excluded. Additionally, studies by the same author or research team conducted within the same time frame were not considered. Studies employing case-control designs or focusing on surveillance, risk factors, Campylobacteriosis outbreaks, genotyping, food handler hygiene, or experimentally inoculated samples (e.g., food or water deliberately spiked with Campylobacter spp. for research purposes) were also excluded. After applying these criteria, full-text screening was conducted on the remaining primary studies. Assessment of study quality and data extraction Selected studies for inclusion were screened for methodological quality by two independent researchers (SS and SBJ) using the standard critical appraisal instruments of the Joanna Briggs Institute Meta-Analysis of Statistics Assessment for Review Instrument (JBI-MAStARI) [34]. Disagreements were resolved through consensus (MDS), and the extracted data, encompassing primary author, publication year, study method, sample size, number of cases, and antibiotic resistance profile, were merged for systematic analysis. Antimicrobial-resistance data extraction and heterogeneity assessment For each included study, data were extracted on the antibiotics tested, the number of resistant isolates, and the total number of isolates examined for each antibiotic to calculate resistance proportions (number resistant / number tested × 100). When only percentages were reported, resistant counts were back-calculated from the total number of isolates when available (File S2). Heterogeneity among studies was anticipated due to differences in geography, host species, sample type, and laboratory testing methods; therefore, statistical heterogeneity was evaluated using I² statistics. Where substantial heterogeneity (I² > 50%) was observed, subgroup analyses were planned according to antibiotic class, Campylobacter species, host source, and study period to explore potential sources of variation. Statistical analysis The RStudio (USA, version 2024.12.0-467) and meta-analysis package for R (Germany, version 4.6) were applied for the meta-analysis. To calculate the pooled prevalence with a 95% confidence interval, a random effects model was utilized. I2 statistic and the prediction interval were assessed to determine heterogeneity among studies. An I² value ≥ 75% indicated substantial heterogeneity, while statistical significance was set at p < 0.05. Publication bias was evaluated with funnel plots and Egger’s test for asymmetry. To stabilize variances, a Freeman-Tukey double arcsine transformation was applied to prevalence data before conducting a random-effects meta-analysis with inverse-variance weighting. Results Search results A total of 989 studies were initially identified through multiple databases, including PubMed, Scopus, Web of Science, Embase, ISC, SID, and Magiran. After removing 460 duplicates, 477 studies were screened. Of these, the following were excluded: studies involving Campylobacter isolates from animals (n = 412); studies focused on conditions such as cancer, Crohn’s disease, Guillain-Barré syndrome, meningitis, pre-dental infections, appendicular syndrome, and irritable bowel syndrome (IBS) (n = 35); studies using MIC methods for antimicrobial screening (n = 1); bioinformatics studies (n = 2); studies on co-infection of Guillain-Barré syndrome and acute brucellosis (n = 1); studies without English abstracts (n = 20); and those without access to the full text (n = 6). Ultimately, 46 studies [35–80] met the inclusion criteria for the systematic review and meta-analysis (Fig. 1). PRISMA flowchart of Campylobacter spp. prevalence in Iran (2000–2025) A Campylobacter identification in the included studies was primarily performed using culture methods and PCR. Notably, most of these studies were conducted in Tehran. While the majority used stool samples for isolation, one study employed rectal swabs instead [51]. Meta-analysis prevalence of Campylobacter spp. We created forest plots to assess the prevalence of Campylobacter spp. across Iran from 2000 to 2025. The meta-analysis revealed an overall pooled prevalence of 8.0% (95% CI: 6.0–10.0%) using a random effects model. The high heterogeneity among the included studies, as indicated by an I² value of 97% (p < 0.0001), suggests significant variability in the data, likely due to differences in study design, sample populations, or diagnostic methods. A linear regression test of funnel plot asymmetry showed an asymmetrical distribution (t = 5.73, df = 44, p-value < 0.0001), with a bias estimate of 7.86 (SE = 1.37) based on Egger’s regression model. This indicates potential publication bias, where studies with higher prevalence rates may have been more likely to be published (Fig. 2A-B). (A) Forest plot showing the pooled prevalence of Campylobacter spp. in Iran from 2000 to March 2025; (B) Funnel plot with 95% confidence limits illustrating the distribution of Campylobacter prevalence estimates A To address this heterogeneity and potential bias, we conducted a sensitivity analysis by identifying and excluding studies that had a significant impact on the heterogeneity and effect size. After this adjustment, the overall pooled prevalence was recalculated as 3.8% (95% CI: 3.6–4.1%, I² = 97.0%), providing a more conservative and robust estimate. In subgroup analyses, among studies that reported species identification, C. jejuni was the dominant species, accounting for 35% (95% CI: 22.0–49.0%) of all Campylobacter-positive isolates, followed by C. coli at 16% (95% CI: 11–22%) (Figs. 3 and 4). (A) Forest plot showing the pooled prevalence of Campylobacter jejuni in Iran from 2000 to March 2025; (B) Funnel plot with 95% confidence limits illustrating the distribution of C. jejuni prevalence estimates (A) Forest plot showing the pooled prevalence of Campylobacter coli in Iran from 2000 to March 2025; (B) Funnel plot with 95% confidence limits illustrating the distribution of C. coli prevalence estimates The prevalence rates of Campylobacter spp. varied across different time periods: 4.0% (95% CI, 0–17.0%, I² = 95.3%) from 2001 to 2006, 4.0% (95% CI, 2.0–7.0%, I² = 97.6%) from 2007 to 2012, 11.0% (95% CI, 7.0–15.0%, I² = 94.2%) from 2013 to 2020, and 6.0% (95% CI, 2.0–11.0%, I² = 93.0%) from 2021 to 2025 (Fig. 5). Therefore, the prevalence of Campylobacter spp. shows a general upward trend over time, with a peak in the 2013–2020 period. Forest plot presenting the pooled prevalence of Campylobacter spp. in Iran over different time intervals between 2000 and March 2025 Meta-analysis of Campylobacter spp. prevalence in patients aged ≤ 10 years Our complementary analysis of 13 studies examining the prevalence of Campylobacter spp. in patients aged ≤ 10 years in Iran indicated an overall pooled prevalence of 6.0% (95% CI, 3.0–9.0%, I² = 92.1%) using a random effects model. Furthermore, the linear regression test for funnel plot asymmetry yielded t = 1.49, df = 11, p-value = 0.16, with a bias estimate of 4.08 (SE = 2.73) (Fig. 6A-B). (A) Forest plot depicting the pooled prevalence of Campylobacter spp. in Iran among patients ≤ 10 years of age from 2000 to March 2025; (B) Funnel plot with 95% confidence limits illustrating the prevalence distribution of Campylobacter spp. in the same age group Sensitivity analysis employing the inverse variance method and restricted maximum-likelihood estimator for tau² revealed a pooled prevalence of 4.0% (95% CI: 4.0–5.0%). The pooled prevalence analysis revealed 45.0% (95% CI, 13.0–80.0%, I² = 98.5%) for C. jejuni and 14.0% (95% CI, 7.0–23.0%, I² = 27.1) for C. coli (Figs. 7 and 8). (A) Forest plot presenting the pooled prevalence of Campylobacter jejuni in Iran among patients ≤ 10 years of age from 2000 to March 2025; (B) Funnel plot with 95% confidence limits depicting the prevalence distribution of C. jejuni in the same age group (A) Forest plot presenting the pooled prevalence of Campylobacter coli in Iran among patients ≤ 10 years of age from 2000 to March 2025; (B) Funnel plot with 95% confidence limits depicting the prevalence distribution of C. coli in the same age group Pooled prevalence of Campylobacter spp. Among patients aged > 10 years Our complementary analysis of 33 studies examining the prevalence of Campylobacter among populations aged over 10 years in Iran indicated an overall pooled prevalence of 8.0% (95% CI, 6.0–11.0%, I² = 97.6%) using a random effects model (Fig. 9A-B). (A) Forest plot depicting the pooled prevalence of Campylobacter spp. in Iran among patients ˃ 10 years of age from 2000 to March 2025; (B) Funnel plot with 95% confidence limits illustrating the prevalence distribution of Campylobacter spp. in the same age group Furthermore, the linear regression test for funnel plot asymmetry yielded t = 5.54, df = 31, p-value < 0.0001, with a bias estimate of 9.11 (SE = 1.64). Sensitivity analysis employing the inverse variance method and restricted maximum-likelihood estimator for tau² revealed a pooled prevalence of 3.7% (95% CI: 3.4-4.0%). The pooled prevalence analysis revealed 32.0% (95% CI, 18.0–47.0%, I² = 98.5%) for C. jejuni and 16.0% (95% CI, 10.0–24.0%, I² = 80.9) for C. coli (Figs. 10 and 11). (A) Forest plot depicting the pooled prevalence of Campylobacter jejuni in Iran among patients ˃ 10 years of age from 2000 to March 2025; (B) Funnel plot with 95% confidence limits illustrating the prevalence distribution of C. jejuni in the same age group (A) Forest plot depicting the pooled prevalence of Campylobacter coli in Iran among patients ˃ 10 years of age from 2000 to March 2025; (B) Funnel plot with 95% confidence limits illustrating the prevalence distribution of C. coli in the same age group Antimicrobial resistance of Campylobacter spp. In this study conducted in Iran on antibiotic resistance in Campylobacter spp., resistance to six antibiotics was examined: nalidixic acid, tetracycline, ciprofloxacin, erythromycin, ampicillin, and gentamicin. The highest resistance was observed to nalidixic acid, with an overall resistance rate of 98% (95% CI, 86.0-100.0%), including 80% in C. jejuni and 58% in C. coli. Tetracycline showed the second-highest resistance at 79% (95% CI, 36.0-100.0%) overall, with 60% of C. jejuni and 66% of C. coli isolates resistant. Resistance to ciprofloxacin was also high, reported at 65% (95% CI, 19.0–99.0%) overall, including 67% in C. jejuni and 72% in C. coli. Erythromycin resistance was observed in 41% (95% CI, 0.0–98.0%) of all isolates, with a significant difference between species: only 14% of C. jejuni showed resistance compared to 72% of C. coli. For ampicillin, the overall resistance was 56% (95% CI, 22.0–87.0%), with 26% resistance in C. jejuni and 34% in C. coli. The lowest resistance was found for gentamicin, with an overall rate of just 7% (95% CI, 0.0–23.0%), including 6% in C. jejuni and 14% in C. coli. Annual resistance rates for selected antibiotics were calculated by dividing the number of resistant C. coli cases by the total number of tested isolates each year, expressed as a percentage. These trends, covering the period from 2007 to 2019, were visualized using LOESS (Locally Estimated Scatterplot Smoothing) to highlight changes over time. The analysis showed a sharp and sustained rise in resistance to ciprofloxacin and tetracycline, with both exceeding 95% by the end of the study period. Resistance to erythromycin remained consistently high throughout, while ampicillin displayed a gradual upward trend. Gentamicin resistance, although increasing, remained below 40%, suggesting it may still retain some clinical effectiveness. Nalidixic acid followed a U-shaped pattern—declining until around 2015, then rising again. When examining resistance in C. jejuni, the data revealed a rapid increase in resistance to ciprofloxacin and tetracycline as well, with both nearing or surpassing 90% in recent years. Erythromycin resistance was also high and stable, indicating persistent selective pressure. In contrast, ampicillin showed a slow but steady increase, while nalidixic acid exhibited a more complex, non-linear trend, possibly reflecting shifts in antibiotic use or evolving resistance mechanisms. Gentamicin remained the antibiotic with the lowest resistance rates, though it too showed a slight upward trend (Fig. 12A-C). Trends in antibiotic resistance rates of (A) Campylobacter spp., (B) C. jejuni, and (C) C. coli in Iran (2000- March 2025) Discussion Acute gastroenteritis remains a major public health challenge worldwide, especially among children under five, where diarrheal diseases rank among the leading causes of mortality [27, 81]. Campylobacter spp. are globally recognized as a leading cause of bacterial gastroenteritis in humans [82]. This study systematically reviews research from Iran between 2000 and 2025 to evaluate the prevalence and antimicrobial resistance patterns of Campylobacter in human samples. Globally, the incidence of campylobacteriosis is rising, although regional data are uneven, with significant gaps particularly in Asia and the Middle East [27]. A recent systematic review (2022) showed that reported Campylobacter spp. diarrhea in children detection rates varied widely across the region in South Asia, ranging from 0.3% to 31.8% [83]. In the United States, Campylobacter is the foremost bacterial cause of diarrhea, responsible for approximately 1.3 million cases annually [84]. Developing countries such as South Africa, India, and Kenya report even higher infection rates in young children [26, 85, 86]. Similarly, studies from the Middle East between 2005 and 2015 have identified Campylobacter spp. as a common cause of pediatric dysentery [76, 87, 88]. In Iran, poultry and domestic animals serve as primary reservoirs for Campylobacter, particularly C. jejuni, which plays a critical role in foodborne transmission. High colonization rates have been documented in poultry flocks. For instance, Babaie Najad Basiri et al. (2016) detected thermophilic Campylobacter spp. in 65.3% of broiler fecal samples, with C. jejuni comprising nearly 80% of the isolates [89]. More recently, Mirmoeini et al. (2023) reported Campylobacter spp. presence in 81% of broiler carcasses, with 31% positive for C. jejuni [90]. Additionally, domestic animals such as cattle, sheep, and goats harbor Campylobacter in their intestines, contributing to transmission through fecal shedding and contamination of meat and dairy products, especially under poor hygiene conditions during slaughter and processing [91, 92]. A 2014–2016 study in West Azerbaijan investigated contamination of poultry meat and offal with Campylobacter spp., identifying a prevalence rate of 37.7% [93]. A survey of 100 broiler flocks in Shiraz (2009) found 76% positive for C. jejuni and/or C. coli, influenced by slaughter age and farm management. Similarly, a molecular survey in southern Iran detected contamination with C. jejuni and C. coli in 53.3% of poultry carcasses [94]. A 2023 systematic review and meta-analysis on the prevalence of Campylobacter in Iran reported pooled prevalence rates of 7.9% in red meat and 5.5% in eggs. These findings highlight that poultry, particularly chicken, remains a major concern for Campylobacter carriage in Iran [95]. Other study results from Qazvin highlighted raw milk as a potential vehicle for Campylobacter transmission and stressed the importance of milk pasteurization and hygiene control [96]. Human infection typically occurs via consumption of undercooked poultry meat, unpasteurized milk, contaminated water, or through cross-contamination during food preparation. Although campylobacteriosis is often self-limiting, it can cause severe complications in immunocompromised individuals [90]. The overall prevalence indicates a moderate but rising burden of Campylobacter infections in Iran, particularly during 2013–2020. To contextualize these findings, a comparative study on diarrheagenic Enterobacteriaceae in Iran reported Shigella spp. as the most prevalent pathogen at 18.0% (95% CI: 0.1–0.2; I²=99%), followed by diarrheagenic Escherichia coli at 11.0% (95% CI: 0–0.15; I²=97%), Salmonella spp. at 9.0% (95% CI: 0–0.1; I²=99%), and Yersinia spp. at 2.0% (95% CI: 0–0.1; I²=94% [97]. The meta-analysis was characterized by substantial heterogeneity (I² > 90% for most analyses), which limits the robustness and interpretability of the pooled estimates. The high heterogeneity observed in our meta-analysis (I² = 97%) may reflect a combination of methodological and contextual factors. For example, variations in study design, population characteristics, and sample size could help explain between-study differences—smaller studies may be more likely to capture localized outbreaks or atypical patterns. In contrast, larger studies often produce more consistent estimates. Diagnostic procedures may have also influenced the results; while we restricted inclusion to studies using stool culture for Campylobacter identification, differences in laboratory techniques and media preparation across centers might plausibly affect detection rates. We acknowledge that we did not perform subgroup analyses based on provincial or regional distinctions, as such stratified data were not consistently available in the included studies. Likewise, our dataset did not allow for a reliable urban–rural comparison. The substantial decrease in pooled prevalence following sensitivity analysis (from 8.0% to 3.8%) suggests that the initial estimate was heavily influenced by a few high-heterogeneity studies, providing a more conservative baseline prevalence. Our systematic search included all Campylobacter spp. as keywords. However, the majority of studies focused exclusively on C. jejuni and C. coli. Only one study—conducted by Sadeghi et al. in 2020 [66]—reported the presence of Campylobacter lari in human gastroenteritis cases, with a very low prevalence. Due to its rare and statistically insignificant occurrence, C. lari was excluded from our meta-analysis of Campylobacter subspecies. C. jejuni predominance aligns with its established role in human gastroenteritis. C. jejuni infections commonly present as acute diarrheal disease, characterized by watery to dysenteric stools, fever, abdominal cramps, weight loss, and malaise. The typical incubation period ranges from 24 to 72 h, with symptoms usually resolving within seven days [98]. Recent Iranian surveillance (November 2021–January 2022) identified Campylobacter spp. in 8.4% of human samples, with C. jejuni comprising 83.3% of isolates [95]. In West Africa, pooled prevalence-primarily based on Nigerian data-was approximately 10% [99]. In developing countries, Campylobacter species are a well-documented cause of pediatric diarrhea, often transmitted via contaminated food and water sources [100]. Most epidemiological data from these regions arise from diarrheal disease surveillance programs [101]. In Southeast Asia, a 2001–2014 study from Singapore revealed C. jejuni to be the dominant isolate (84–100%), followed by C. coli (0–4%), C. lari (0–0.2%), and other Campylobacter species (0–12%) [102]. While our primary focus was on estimating the prevalence and antimicrobial resistance patterns of Campylobacter species, our subgroup analyses provide indirect evidence regarding the species-specific contribution to disease across age groups, which are often associated with differing clinical presentations. Due to inconsistencies in age reporting across the 46 studies included in our meta-analysis-where age ranges were either broadly defined or not reported precisely standardized the inclusion criteria by categorizing studies into defined age groups (e.g., cases ≤ 10 years and individuals ˃ 10 years). This stratification aimed to improve comparability and to explore potential differences in Campylobacter prevalence across age groups, particularly given the greater clinical significance of Campylobacter-associated gastroenteritis in young children due to their immature immune systems. Age-stratified analyses suggest C. jejuni predominates across age groups, potentially reflecting differences in exposure or immunity. These findings suggest age-related variations in Campylobacter subspecies distribution, with C. jejuni being more prevalent across all age groups but disproportionately higher in older individuals. This could be attributed to differences in exposure sources (e.g., foodborne vs. environmental), dietary habits, or host immune response mechanisms. Further research is needed to clarify whether these patterns reflect true epidemiological differences or are influenced by study design, geographic factors, or diagnostic methods. In South Asia, a 2022 review revealed wide variability in Campylobacter prevalence detection rates (0.3–31.8%) across India, Bangladesh, Pakistan, and Nepal, with a pooled prevalence of 6.96% [83]. Similarly, in Southeast Asia, Campylobacter prevalence was estimated at 7.1% in children and 3.0% in adults [103], while in Thailand, 13.3% of gastroenteritis cases were linked to Campylobacter spp. Among these, 66% of isolates from farm workers were C. coli, whereas 62% from pediatric cases were C. jejuni [103, 104]. In Lebanon (2018), a six-month cohort study found a prevalence of 12.02% in children under 12 years [20]. A broader Middle East study (2010–2021) involving Egypt, Iran, Turkey, Lebanon, Israel, Jordan, and Palestine reported an overall prevalence of 22%, with higher rates in diarrheic patients (23%) and lower rates in high-risk groups (14%). C. jejuni was predominant (16% in diarrhea patients; 9% in high-risk groups), followed by C. coli (3% and 8%, respectively) [105]. Campylobacteriosis incidence is influenced by seasonal factors, although no universal seasonal pattern has been confirmed. Temperature, climate, and biosecurity practices in poultry production are likely contributing factors [106–108]. In Iran, the highest prevalence was recorded from June to October, with a 2021 study by Barati et al. detecting Campylobacter in 14.8% of pediatric gastrointestinal cases using multiplex PCR, of which 95.2% were C. jejuni and 4.8% C. coli [62]. Culture-based methods yielded a lower detection rate (6.71%). Insects, attracted to poultry farms with poor biosecurity, may also act as mechanical vectors [109]. Although antimicrobial treatment is typically not indicated for uncomplicated campylobacteriosis, antibiotics are essential in severe or prolonged cases and are commonly used in poultry farming for both therapeutic and prophylactic purposes. Novel approaches, such as bacteriocins [110, 111], vaccines [112], and probiotics [113] are under investigation, but antibiotic misuse has led to rising resistance [114, 115]. Numerous studies are exploring non-antibiotic alternatives for treating bacterial infections [116–118]. Despite these efforts, antibiotic resistance has become a global crisis, contributing to an estimated 1.2 million deaths in 2019 and potentially rising to 10 million deaths annually by 2050 if current trends continue [119, 120]. Our meta-analysis, based on studies published in Iran (2000 to 2025), evaluated antibiotic options for the treatment of Campylobacter gastroenteritis across different lines of therapy. In our study, the antibiotics nalidixic acid, tetracycline, ciprofloxacin, erythromycin, ampicillin, and gentamicin were chosen based on both their therapeutic relevance and their role in antimicrobial resistance surveillance for Campylobacter spp. Ciprofloxacin and erythromycin are consistent with WHO AWaRe [121] and the Iranian national treatment guidelines [122] for acute bacterial gastroenteritis and Campylobacter infection, representing recommended first-line and alternative therapies, respectively. The remaining agents (ampicillin, tetracycline, gentamicin, and nalidixic acid) were included for comparative susceptibility profiling, as they are commonly used in Iranian laboratories and provide valuable data on resistance trends over time. This approach aligns with WHO recommendations for monitoring antimicrobial resistance patterns to inform empiric treatment policy updates. The findings revealed high levels of antimicrobial resistance among Campylobacter isolates, with resistance rates of 98.0% to nalidixic acid and 79.0% to tetracycline. These levels were higher than those in the Middle East Asia [105] and Europe [30, 123]. Previous studies have also reported increasing tetracycline resistance in both human and animal populations since 1999 [124]. Fluoroquinolones are generally the preferred choice for treating diarrhea caused by Campylobacter infections. Nevertheless, substantial resistance to ciprofloxacin has been noted in both C. coli and C. jejuni isolates from humans and food-producing animals across Europe and numerous other regions [125, 126]. Extensive reports have documented fluoroquinolone resistance among both human and farm animal isolates of Campylobacter [125, 127]. In the U.S.A., the CDC reported ciprofloxacin resistance in 28% of C. jejuni and 38% of C. coli isolates in 2017, while South Korean studies documented 100% resistance to ciprofloxacin and nalidixic acid [128]. In Iran, ciprofloxacin resistance increased to 65.0% (95% CI: 19.0–99.0%) over the study period. Similarly, resistance in poultry meat samples reached 100% for both ciprofloxacin and nalidixic acid, with tetracycline resistance at 93.9% in C. jejuni and 83.3% in C. coli [122]. These findings reflect the serious risk posed by poultry as a reservoir for resistant strains. In line with our results, Khademi et al. (2020) confirmed this resistance trend in Iran [129]. In southwestern Iran, 55.4% of chicken carcasses were positive for Campylobacter, with 92.9% of isolates resistant to at least one antibiotic, especially tetracycline (78%), ciprofloxacin (62%), and nalidixic acid (59%) [130]. A 2008–2009 meat survey found 6.9% contamination in red meat, highest in lamb (12%), with substantial resistance to tetracycline (68%) and ciprofloxacin (46%) [131]. Most Campylobacter strains are inherently resistant to many beta-lactams, mainly first- and second-generation penicillins and cephalosporins [132]. Our study also found that 56% of Campylobacter isolates from gastroenteritis cases in Iran were resistant to ampicillin. Specifically, the resistance rates were 26% for C. jejuni and 34% for C. coli. Macrolides, such as erythromycin, remain important alternatives for treating resistant strains. Erythromycin resistance in Iranian isolates reached 41.0% from 2000 to 2023. A longitudinal surveillance study (1954–2023) worldwide revealed that macrolide-resistant Campylobacter was more common in China than in other countries [133]. Taiwanese whole-genome sequencing (2016–2019) showed 13.2% resistance to erythromycin alone, and 12.3% when combined with ciprofloxacin [134]. In a study conducted in Shanghai, China, between 2012 and 2019, a significant difference was observed in erythromycin resistance between C. jejuni and C. coli. The resistance rate in C. jejuni was relatively low at 2.5%, while C. coli exhibited a much higher resistance rate of 59.2% [135]. Our meta-analysis also revealed a notable difference in erythromycin resistance between C. coli and C. jejuni, with resistance rates of 72% and 14%, respectively. This sharp disparity underscores the much higher level of macrolide resistance in C. coli compared to C. jejuni in cases of Campylobacter-related gastroenteritis. Our study found that while C. jejuni was more prevalent than C. coli in human cases of Campylobacter-associated gastroenteritis in Iran over the past 25 years, C. coli showed higher resistance to several antibiotics-including ampicillin, ciprofloxacin, erythromycin, gentamicin, and tetracycline. In Asia, resistance to fluoroquinolones in C. jejuni remained relatively stable over the last 23 years. However, resistance to tetracyclines and beta-lactams steadily increased. Similarly, C. coli in Asia has shown rising resistance to beta-lactams and aminoglycosides since 2009. Although tetracycline resistance in C. coli slightly declined between 2015 and 2019, the overall trend remains upward. In contrast, fluoroquinolone resistance in C. jejuni has been steadily increasing in Europe, North America, and South America [133]. This systematic review, while comprehensive in its assessment of Campylobacter prevalence and antimicrobial resistance in human samples in Iran from 2000 to 2025, is subject to several limitations. First, despite extensive literature retrieval, regional disparities in research coverage were evident, with some provinces underrepresented or lacking recent data. This uneven distribution may limit the national representativeness of our findings. Second, the heterogeneity in diagnostic methodologies across studies-including differences in culture conditions, PCR protocols, and antibiotic susceptibility testing-may have influenced the reported prevalence and resistance rates, complicating cross-study comparisons. Many studies relied on culture-based techniques, which may underestimate the true prevalence of Campylobacter due to the organism’s fastidious nature. Another notable limitation is the scarcity of molecular typing data across the studies, which restricts our ability to track clonal spread, identify resistance genes, or determine precise sources of infection. Moreover, while foodborne transmission is a well-established route, the absence of molecular tracing between human and food isolates limited the ability to draw firm conclusions about zoonotic or food chain links. Although clinical disease severity was not uniformly reported across the included studies, the age-based distribution of species prevalence indirectly suggests that C. jejuni is more frequently associated with human gastroenteritis across all age groups and may be responsible for a larger proportion of symptomatic cases, particularly in older individuals. This aligns with existing literature, which associates C. jejuni more strongly with severe gastroenteritis and post-infectious complications (e.g., Guillain-Barré syndrome) compared to C. coli. However, due to the lack of consistent clinical outcome data linked directly to specific Campylobacter species in the reviewed studies, we were unable to statistically assess the association between individual species and disease severity or type. We acknowledge this as a limitation and recommend that future studies report detailed clinical correlations alongside molecular identification to better elucidate species-specific pathogenicity. Moreover, the study did not evaluate the association between specific Campylobacter species (C. jejuni vs. C. coli) and the clinical manifestations of gastroenteritis, as this analysis was not feasible due to the limited availability of species-specific clinical data in the included studies. Despite these limitations, this review provides a critical foundation for understanding Campylobacter epidemiology in Iran. Future research should aim to standardize diagnostic and antimicrobial susceptibility protocols to improve comparability across studies. Longitudinal surveillance with molecular epidemiological tools such as whole-genome sequencing will be vital for tracking resistance trends and outbreak sources. In addition, further investigations should prioritize under-sampled regions and vulnerable populations to build a more complete national picture. Lastly, integrating One Health approaches that examine Campylobacter’s human, animal, and environmental reservoirs will be essential for developing effective public health interventions and antimicrobial stewardship policies. Conclusion This study analyzed the trends in Campylobacter-associated gastroenteritis and corresponding antibiotic resistance in Iran over 25 years, from 2000 to 2025. During this time, the incidence of Campylobacter infections has increased, ranking it as the fourth most common bacterial cause of gastroenteritis in the country, following Shigella spp., E. coli, and Salmonella spp. The pooled prevalence of Campylobacter species was found to be 8.0%, with the highest rates recorded between 2013 and 2020. Among the identified species, C. jejuni was the most prevalent (35%), followed by C. coli (16%), while C. lari was rarely detected. Interestingly, although C. jejuni was more prevalent than C. coli, the latter exhibited higher resistance to the most commonly used antibiotics in Iran. Among the available treatment options, gentamicin emerged as the most effective, with only a 7% resistance rate, making it suitable for severe or systemic infections, despite its limitation as an injectable drug. Erythromycin showed moderate resistance at 41% and may still be used empirically, preferably supported by susceptibility testing. In contrast, antibiotics such as nalidixic acid (98% resistance), tetracycline (79%), ciprofloxacin (65%), and ampicillin (56%) showed high resistance rates and are therefore not recommended for treatment. These findings underscore the urgent need for ongoing surveillance and the development of updated treatment guidelines to ensure effective management of Campylobacter infections in Iran. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 2 Acknowledgements The authors gratefully acknowledge the support of the Research Council of Tarbiat Modares University, Iran. The authors would also like to thank the Clinical Research Development Unit of Kashan Shahid Beheshti Hospital. Abbreviations Campylobacter jejuni Campylobacter coli Preferred Reporting Items for Systematic Reviews and Meta-Analyses Joanna Briggs Institute Meta-Analysis of Statistics Assessment for Review Instrument Author contributions BB and AK conceptualized the study, supervised the research process, and finalized the manuscript. MDS contributed to data extraction, drafted the initial manuscript, and participated in revisions. FH performed the data analysis and provided statistical oversight and validation of the extracted data. S. Shams assisted in drafting and revising the manuscript. S. Safaei and SBJ were involved in data extraction. All authors reviewed and approved the final version of the manuscript. Funding The Research Council of Tarbiat Modares University supported the study. Data availability The datasets used and/or analyzed during the current work are available from the corresponding authors with no restriction. Declarations Ethics approval and consent to participate None. Consent for publication None. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Contributor Information Bita Bakhshi, Email: B.bakhshi@modares.ac.ir. Anoshirvan Kazemnejad, Email: kazem_an@modares.ac.ir. Reference list Associated Data Supplementary Materials Supplementary Material 1 Supplementary Material 2 Data Availability Statement The datasets used and/or analyzed during the current work are available from the corresponding authors with no restriction.